Last updated: February 22, 2026
What Is the Product?
NDC 00527-1949 refers to Tocilizumab Injection, marketed under the brand name Actemra. It is an immunosuppressive monoclonal antibody used primarily for rheumatoid arthritis, cytokine release syndrome, and other inflammatory conditions.
Market Size and Trends
Current Market Landscape
- Global Sales (2022): $4.7 billion, with a compound annual growth rate (CAGR) of approximately 8% from 2019 to 2022.
- US Market Share: 55% of global sales, driven by high prevalence of rheumatoid arthritis (RA) and expanded indications.
- Licensed Indications:
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Cytokine release syndrome associated with CAR T-cell therapy
- Giant cell arteritis (FDA approval in 2022)
Market Drivers
- Increasing prevalence of autoimmune diseases
- Expanded FDA approvals (notably for giant cell arteritis)
- Rise in biologics adoption over small molecules
- Updated treatment guidelines favoring biologics in early RA
Competitive Landscape
| Product Name |
Developer |
Mechanism of Action |
Approximate 2022 US Sales |
Market Share (US) |
| Tocilizumab (Actemra) |
Roche |
IL-6 receptor inhibitor |
$2.7 billion |
61% |
| Sarilumab (Kevzara) |
Sanofi, Regeneron |
IL-6 receptor inhibitor |
$600 million |
14% |
| Others |
Various (biosimilars) |
IL-6 pathway |
<$500 million |
23% |
Biosimilar Development
- Several biosimilars in late-stage development or approved in Europe, but none approved in the US as of 2023.
- Biosimilar entry expected in 2024-2025, potentially reducing prices.
Price Trends and Projections
Current Pricing
| Formulation |
US List Price (per 80 mg/0.8 mL) |
Average Wholesale Price (AWP) |
Estimated Net Price (after discounts) |
| Tocilizumab (Actemra) Injection |
$3,400–$3,600 |
~$3,200 |
~$2,000–$2,500 |
Pricing varies based on dosing, indication, and payer contracts. The drug is dosed based on weight (often 4-8 mg/kg every 4 weeks).
Price Trends (2019–2022)
- Stable list prices with minor fluctuations.
- Slight reductions in net prices driven by payer negotiations and discounts.
- Biosimilar entry anticipated to generate a 20–30% price reduction over the next 2 years.
Price Projections (2023–2027)
- List prices expected to remain stable.
- Net prices likely to decrease by 10–15% annually after biosimilar market entry.
- Biosimilars could reduce prices by 25–35% compared to current list prices.
Revenue Impact and Market Penetration
- Biosimilar competition could reduce Roche’s US revenues by 30–40% by 2026.
- However, the drug's expanded indications and chronic usage sustain revenue streams.
Regulatory and Policy Factors
- FDA Approvals: Recent approval for giant cell arteritis expands the patient pool.
- Pricing Policies: Medicare and private payers increasingly pressure for biosimilar adoption, influencing net prices.
- Global Variations: Pricing in Europe and emerging markets is generally lower, often 50–70% of US prices.
Key Takeaways
- The rheumatoid arthritis segment remains the core market for Tocilizumab, with steady growth driven by new indications.
- Biosimilar competition is imminent, likely leading to notable price reductions.
- Roche's revenues are vulnerable to biosimilar entry but are supported by multiple indications and ongoing pipeline expansion.
- US net prices could decline annually by 10–15% post-biosimilar entry, with total market share decreasing correspondingly.
FAQs
1. When are biosimilars for Tocilizumab expected in the US?
Biosimilars are likely to enter the US market between 2024 and 2025, following approval in Europe and pending FDA approval.
2. What factors influence the price of Tocilizumab?
Pricing is influenced by formulation, indication, payer negotiations, manufacturer discounts, and biosimilar competition.
3. How will biosimilar entry affect Roche’s sales?
Biosimilar entry could reduce Roche’s US revenues by up to 40%, depending on market penetration and pricing discounts.
4. Are there approved biosimilars for Tocilizumab outside the US?
Yes, several biosimilars are approved in Europe and other territories, typically priced 50–70% lower than branded versions.
5. What is the primary driver of growth in the Tocilizumab market?
Expanded indications and increased adoption in autoimmune and inflammatory conditions.
Sources
[1] EvaluatePharma. (2023). World Preview 2023. Retrieved from https://www.evaluate.com
[2] IQVIA. (2022). United Statespharmaceutical market report.
[3] FDA. (2022). Biosimilar Product Information. Retrieved from https://www.fda.gov/BiologicsBloodVaccines/Biosimilars
[4] Roche. (2023). Actemra US Label.
[5] Statista. (2023). Biologic drug sales in the US.
